or
Bookmark and Share
Expression of fructose 1,6 bisphosphate aldolase in transgenic plants
   
Document Number
US Patent 6716474
Issued Date
April 6, 2004
Link
Inventors
Map
Abstract
Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
2
Comments:
no comments yet
Owner
Monsanto Technology LLC (St. Louis, MO)
Published
April 6, 2004
Application Number
09/923,109
Filed
August 6, 2001
US Classification
426/637  
Int'l Classification
C12N   15/82   (20060101)   C12N   9/88   (20060101)  
Examiner
Parent Case
This application is a divisional application Ser. No. 09/098,219 filed Jun. 16, 1998, now U.S. Pat. No. 6,441,277, which is based on U.S. Provisional application Serial No. 60/049,995, filed Jun. 17, 1997.
USPTO Field of Search
800/298   426/560   426/637   435/232  
Related Patents
Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us